The TCR therapy showed strong efficacy and durability in patients with previously treated melanoma. A Phase III pivotal trial is due to start in December.

With more advanced therapies gaining approval, companies at ARM’s Cell and Gene Meeting on the Mesa considered hurdles to making their products more broadly available and developing them for larger indications.

New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.

Pridopidine, sebetralstat and mirdametinib, which are novel treatments that are yet to be approved anywhere in the world, are among the latest products for which marketing applications are now under review by the European Medicines Agency.